VAXART INC. DL-10
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus v… Read more
Market Cap & Net Worth: VAXART INC. DL-10 (NB11)
VAXART INC. DL-10 (F:NB11) has a market capitalization of $93.64 Million (€91.22 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #18568 globally and #1960 in its home market, demonstrating a 9.32% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VAXART INC. DL-10's stock price €0.38 by its total outstanding shares 240059770 (240.06 Million).
VAXART INC. DL-10 Market Cap History: 2015 to 2026
VAXART INC. DL-10's market capitalization history from 2015 to 2026. Data shows change from $433.44 Million to $93.64 Million (-14.01% CAGR).
VAXART INC. DL-10 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VAXART INC. DL-10's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of NB11 by Market Capitalization
Companies near VAXART INC. DL-10 in the global market cap rankings as of March 19, 2026.
Key companies related to VAXART INC. DL-10 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
VAXART INC. DL-10 Historical Marketcap From 2015 to 2026
Between 2015 and today, VAXART INC. DL-10's market cap moved from $433.44 Million to $ 93.64 Million, with a yearly change of -14.01%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €93.64 Million | 0.00% |
| 2025 | €93.64 Million | -43.70% |
| 2024 | €166.33 Million | +32.72% |
| 2023 | €125.33 Million | -43.33% |
| 2022 | €221.13 Million | -84.11% |
| 2021 | €1.39 Billion | +15.70% |
| 2020 | €1.20 Billion | +1985.47% |
| 2019 | €57.66 Million | -88.06% |
| 2018 | €482.97 Million | +367.78% |
| 2017 | €103.25 Million | -64.61% |
| 2016 | €291.76 Million | -32.69% |
| 2015 | €433.44 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of VAXART INC. DL-10 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $93.64 Million USD |
| MoneyControl | $93.64 Million USD |
| MarketWatch | $93.64 Million USD |
| marketcap.company | $93.64 Million USD |
| Reuters | $93.64 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.